TLDR:
- Merck’s Corporate Venture M Ventures arm has backed Nucleai to advance its spatial AI biomarker.
- The funding will accelerate the deployment of Nucleai’s spatial analysis technology, empowering pathologists with precision in disease diagnosis and treatment.
Merck’s Corporate Venture arm, M Ventures, has invested in Nucleai to advance its first-in-class Spatial AI Biomarker. The investment aims to drive the deployment of Nucleai’s spatial analysis technology, which transforms biopsy slides into dynamic AI-guided action plans. This technology empowers pathologists with the intelligence to anticipate and navigate complex diseases, such as cancer, with unmatched precision. By integrating AI algorithms for prospective patient enrollment in clinical trials, Nucleai is pioneering a personalized medicine approach, enhancing treatment accuracy and efficiency for advanced therapeutics like ADCs and bi-specifics.
The funding from M Ventures supports Nucleai’s vision of ensuring that every next-generation therapeutic is accompanied by an AI-enabled companion diagnostic, optimizing patient treatment pathways. Nucleai’s AI-powered platform analyzes pathology images and spatial data at cellular and tissue levels, providing insights into the tumor microenvironment and cellular morphology. This technology enhances drug development, refines biomarker discovery, and improves therapeutic targeting precision, ultimately leading to more effective and personalized treatment options for patients.
The funding will also help Nucleai scale its spatial AI technology for patient enrollment in clinical trials and support its work in emerging areas like immunotherapies, antibody-drug conjugates, and bi-specifics. By moving beyond traditional pathology analysis, Nucleai leverages AI to create dynamic, digital maps from biopsy samples, offering in-depth contextual views that underpin the development of novel therapeutics. This investment from M Ventures reflects Nucleai’s growing momentum in the life sciences industry and highlights its commitment to revolutionizing disease diagnosis and treatment through AI-powered spatial biomarkers.
